相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
Niels Weinhold et al.
HAEMATOLOGICA (2021)
Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets
Jessica Burroughs Garcia et al.
CELLS (2021)
Chromosome 1q21 abnormalities in multiple myeloma
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2021)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides
Jiadai Xu et al.
LEUKEMIA & LYMPHOMA (2020)
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
Wen Gao et al.
CANCER MEDICINE (2020)
1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
Xiaozhe Li et al.
ONCOLOGIST (2019)
Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis
Phaik Ju Teoh et al.
BLOOD (2018)
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis et al.
HAEMATOLOGICA (2017)
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis et al.
HAEMATOLOGICA (2017)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
Norbert Grzasko et al.
HEMATOLOGICAL ONCOLOGY (2013)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
B Zhang et al.
BLOOD (2002)